MD Anderson Cancer Center

The University of Texas

Houston, TX
Website
(888) 354-2873Refer Patient

Accepting patients

SUCCESSOR-1

Phase 3 Clinical Trial Evaluating the Safety and Effectiveness of Investigational Drug Mezigdomide in Combination with Bortezomib and Dexamethasone Compared to Pomalidomide, Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Learn more
  • CELMoD
  • Randomization
  • Phase 3

Accepting patients

KarMMa-9

Phase 3 Clinical Trial Comparing the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance to Approved Lenalidomide Maintenance Alone in Patients with Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Stem Cell Transplant
Learn more
  • CAR T Cell
  • Immunomodulatory Drug
  • BCMA
  • Randomization
  • Phase 3
Get personalized results in 60 seconds
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials

Accepting patients

QUINTESSENTIAL

A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
Learn more
  • CAR T Cell
  • GPRC5D
  • Phase 2

Accepting patients

CA088-1005

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component
Learn more
  • Bispecific Antibody
  • CAR T Cell
  • CELMoD
  • BCMA
  • GPRC5D
  • Phase 1
2 hidden based on your filters. Show All

Filters

Diagnosis

Treatment History

Prior BCMA Therapy

Advanced Filters

Classifications

Trial Enrollment Status